Huijuan Cao

Dr. Huijuan Cao

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 January 2013 in Chinese Medicine
Verified
Journal Article
Open access
PDF file
NWNan Wang
Nan Wang
Xin-Luan WangXin-Luan Wang
Xin-Luan Wang
WCWenxiang Cheng
Wenxiang Cheng
HCHuijuan Cao
Huijuan Cao
PZPeng Zhang
Peng Zhang
LQLing Qin
Ling Qin
Puerarin (daidzein 8-C-glucoside) has potential on preventing osteoporosis. This study aims to investigate the effects of puerarin on osteogenesis and adipogenesis in vitro. CCK-8 assay, alkaline phosphatase (ALP) activity and Alizarin Red S were used to measure the effects of puerarin on proliferation, osteoblastic differentiation, and mineralization in osteoblast-like MC3T3-E1 cells. The effects of puerarin on adipogenesis were measured by Oil Red O staining and intracellular triglyceride level in preadipocyte 3T3-L1 cells. The mRNA and protein levels of osteogenesis- and adiopogenesis-related factors were detected by qRT-PCR and western blot, respectively. Further, the secreted osteocalcin levels and nuclear translocation of β-catenin were detected by ELISA and immunofluorescence assay, respectively. As to osteogenesis, puerarin could stimulate proliferation (1 μM, P = 0.012; 10 μM, P = 0.015; 20 μM, P = 0.050), ALP activity (20 μM, P = 0.008) and calcium nodule formation (20 μM, P = 0.011) in a dose-dependent manner. Puerarin (20 μM) promoted osteocalcin secretion (P = 0.004) and the protein expression of both osteopontin (P = 0.001) and osteoprotegerin (P = 0.003). As to adipogenesis, puerarin suppressed adipocytes formation and intracellular triglyceride level (P = 0.001). In addition, puerarin (20 μM) decreased the mRNA and protein levels of CCAAT/enhancer binding protein α (P = 0.001, P = 0.002), proliferator-activated receptor γ (P = 0.005, P = 0.003), and adipocyte lipid-binding protein 4 (P = 0.001, P = 0.001). Moreover, phosphorylation of AKT1-Ser437 (10 μM, P = 0.003; 20 μM, P = 0.007) and GSK-Ser9 (10 μM, P = 0.005; 20 μM, P = 0.003), and the nuclear translocation of β-catenin (10 μM, P = 0.006; 10 μM, P = 0.002) were increased in 3T3-L1 cells treated by puerarin. Puerarin promoted osteogenesis and inhibited adipogenesis in vivo, and Akt/GSK-3β/β-catenin signaling pathway was involved in the suppression of adipogenesis.

5 October 2022 in Bioengineering
Verified
Journal Article
Open access
PDF file
XZXiaoting Zhang
Xiaoting Zhang
Xin-Luan WangXin-Luan Wang
Xin-Luan Wang
WLWayne Lee
Wayne Lee
LFLu Feng
Lu Feng
BWBin Wang
Bin Wang
GLGang Li
Gang Li
We develop a poly (lactic-co-glycolic acid)/β-calcium phosphate (PLGA/TCP)-based scaffold through a three-dimensional (3D) printing technique incorporating icaritin (ICT), a unique phytomolecule, and secretome derived from human fetal mesenchymal stem cells (HFS), to provide mechanical support and biological cues for stimulating bone defect healing. With the sustained release of ICT and HFS from the composite scaffold, the cell-free scaffold efficiently facilitates the migration of MSCs and promotes bone regeneration at the femoral defect site in the ovariectomy (OVX)-induced osteoporotic rat model. Furthermore, mechanism study results indicate that the combination of ICT and HFS additively activates the Integrin–FAK (focal adhesion kinase)–ERK1/2 (extracellular signal-regulated kinase 1/2)–Runx2 (Runt-related transcription factor 2) axis, which could be linked to the beneficial recruitment of MSCs to the implant and subsequent osteogenesis enhancement. Collectively, the PLGA/TCP/ICT/HFS (P/T/I/S) bioactive scaffold is a promising biomaterial for repairing osteoporotic bone defects, which may have immense implications for their translation to clinical practice.

12 April 2025 in Journal of Orthopaedic Translation
Verified
Journal Article
Open access
HCHuijuan Cao
Huijuan Cao
KSKeda Shi
Keda Shi
JLJing Long
Jing Long
YLYanzhi Liu
Yanzhi Liu
XMXiangbo Meng
Xiangbo Meng
Xin-Luan WangXin-Luan Wang
Xin-Luan Wang
Steroid-associated osteonecrosis of the femoral head (SONFH) is a refractory disease characterized by progressive bone destruction. Clinical evidence suggests that SONFH may extend beyond the intra-capital region to the femoral neck, metaphysis, and even diaphysis, increasing the risk of subtrochanteric fractures and implant loosening post-surgery. While our previous study demonstrated that platelet-derived growth factor-BB (PDGF-BB) promotes reparative osteogenesis in the femoral head, its effects on cortical bone quality in the extended diaphyseal regions under steroid-associated osteonecrosis (SAON) remain unclear. This study aims to investigate whether PDGF-BB could mitigate cortical bone deterioration in the femoral diaphysis during SAON progression. SAON was induced by repeated lipopolysaccharide (LPS) and methylprednisolone (MPS) injections in rabbits. At 2, 4, and 6 weeks after SAON induction, PDGF-BB was intramedullary injected into the proximal femur. Xylenol orange and Calcein green were injected subcutaneously into rabbits on days 14 and 4 before euthanasia. At 3 days after last PDGF-BB treatment, micro-fil perfusion was performed for angiography. Then the femur shaft was dissected for micro-computed tomography (μCT)-based angiography, μCT-based cortical bone geometry, and histological analysis. With regard to the macrophage infiltration and activated osteoclast function in osteonecrosis regions during SAON progression, RAW 264.7 cells were utilized to evaluate the effect of PDGF-BB on macrophage polarization and osteoclasts activity in vitro. In this study, osteonecrosis extended to the femoral diaphysis, accompanied by vascular disruption (reduced CD31+ vessels), sensory nerve degeneration (decreased CGRP + fibers), and cortical bone destruction, at 6 weeks post-SAON induction. While PDGF-BB treatment significantly attenuated SAON progression in the femoral diaphysis, restoring blood supply (angiography) and improving cortical bone geometry (μCT). Histologically, PDGF-BB enhanced periosteal and endosteal osteogenesis while suppressing osteoclastic resorption. In vitro, PDGF-BB not only could modulate M1-type macrophages polarization to reduce inflammatory response, but also subsequently afford a secondary source of bioactivity factors during osteoclasts formation process to restore the osteogenic microenvironment, suggesting a dual role in resolving inflammation and enhancing bone remodeling. SAON progression leads to diaphyseal cortical bone deterioration, while PDGF-BB application could restore the osteogenic microenvironment and drive cortical bone remodeling during SAON progression. These findings suggest that PDGF-BB could serve as a potential candidate for attenuating the progression of SAON. Local delivery of PDGF-BB during surgical interventions for SONFH may enhance cortical bone repair and improve mechanical stability, offering a clinically viable strategy to achieve better long-term outcomes.